| High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia S Müller, T Bexte, V Gebel, F Kalensee, E Stolzenberg, J Hartmann, ... Frontiers in immunology 10, 3123, 2020 | 104 | 2020 |
| CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma T Bexte, J Alzubi, LM Reindl, P Wendel, R Schubert, ... Oncoimmunology 11 (1), 2081415, 2022 | 43 | 2022 |
| Immunotherapy with NK cells: recent developments in gene modification open up new avenues LM Reindl, N Albinger, T Bexte, S Müller, J Hartmann, E Ullrich Oncoimmunology 9 (1), 1777651, 2020 | 36 | 2020 |
| Arming immune cells for battle: A brief journey through the advancements of t and nk cell immunotherapy P Wendel, LM Reindl, T Bexte, L Künnemeyer, V Särchen, N Albinger, ... Cancers 13 (6), 1481, 2021 | 35 | 2021 |
| CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML N Albinger, T Bexte, L Buchinger, P Wendel, A Al-Ajami, A Gessner, ... Blood 140 (Supplement 1), 4558-4559, 2022 | 12 | 2022 |
| Non-viral sleeping beauty transposon engineered CD19-CAR-NK cells show a safe genomic integration profile and high antileukemic efficiency T Bexte, L Botezatu, C Miskey, J Campe, LM Reindl, V Gebel, WS Wels, ... Blood 138, 2797, 2021 | 11 | 2021 |
| Nonviral technologies can pave the way for CAR-NK cell therapy T Bexte, LM Reindl, E Ullrich Journal of Leukocyte Biology 114 (5), 475-486, 2023 | 6 | 2023 |
| Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors T Bexte, L Botezatu, C Miskey, F Gierschek, A Moter, P Wendel, ... Molecular Therapy, 2024 | 4 | 2024 |
| CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells T Bexte, N Albinger, A Al Ajami, P Wendel, L Buchinger, A Gessner, ... Nature Communications 15 (1), 8439, 2024 | 1 | 2024 |
| The RHOA Mutation G17V Does Not Lead to Increased Migration of Human Malignant T Cells but Is Associated with Matrix Remodelling K Merk-Ahmad, J Bein, S Scharf, H Schäfer, T Bexte, E Ullrich, AG Loth, ... Cancers 15 (12), 3226, 2023 | 1 | 2023 |
| Empowering virus-free CAR immune cell therapies T Bexte, E Ullrich Molecular Therapy, 2024 | | 2024 |
